Advertisement
The full program was concluded over about 4 months, starting with thedevelopment of a high-performance cell line development at Selexis, followedby cell transfer and manufacturing at Artelis. The culture media usedthroughout the study was industry standard cGMP grade and void of serum or anyanimal derived components.
Advertisement
Dr. Igor Fisch, Co-founder and CEO of Selexis commented on theachievements:
"The productivity and stability of the Selexis high-performance cell linesare a perfect fit for the iCELLis(TM) technology, which has the ability toreach incredibly high-cell-densities of up to 250 mio cells per ml". "Theusefulness and potential applications of the combined approach could stretchacross the biotech industry, beyond just large scale bioproduction".
Dr. Jose Castillo, Co-founder and President of Artelis commented on theachievements:
"These results show the power of the iCELLis(TM) technology. Whencombined with a high-performance cell line, like one from Selexis', we havethe opportunity to reach ultra high productivity levels." "We firmly believethe iCELLis(TM) system will change the approach companies take for the smalland large scale production of recombinant proteins."
Further details on this milestone achievement will be presented at theupcoming Bioprocess International Conference being held in Anaheim,California, September 23 -- 26, 2008.
Artelis and Selexis plan to expand the testing of the combinedtechnologies by evaluating the iCELLis(TM) platform with Selexis generatedHEK293 cells lines.
About the Artelis iCELLis(TM) Technology:
iCELLis (TM) is a proprietary, single-use, technology developed byArtelis. iCELLis(TM) is designed to achieve and maintain high-cell densitieson macrocarriers in a fixed-bed system. Achieving high-cell densities allowscompact iCELLis(TM) bioreactors to equal the productivity of much largerstirred-tank units. Depending on cell type and process, iCELLis(TM) canachieve 20-100x the volumetric productivity of a stirred-tank bioreactor.
iCELLis(TM) represents the next generation of disposable bioreactortechnology, enabling process intensification in upstream processing byreducing bioreactor scale and simplifying operations.
About Artelis:
Artelis is an international and innovative SME founded in 2005.Capitalised by an American company listed on NASDAQ, Artelis is the privilegedpartner of world-leading pharmaceutical groups. The company has broadexperience with disposable technologies: Artelis developed the Newmix(R) JetDrive(TM), disposable mixing system, and co-developed the Nucleo(TM)disposable bioreactor together with ATMI Lifesciences and Pierre GuerinBiolafitte. Artelis is concerned by the process intensification needs in thebiotech industry and dedicated to process development in disposabletechnologies. Artelis' mission is to create the future means of producingproteins, cells and viruses for key markets: monoclonal antibodies, celltherapy, vaccines and gene therapy. For more information, please visithttp://www.artelis.be.
About the Selexis Genetic Elements(TM):
Selexis Genetic Elements (TM) are applied to control the dynamicorganization of transgenes in the chromatin of eukaryotic production cells.Th
